Solid Biosciences (SLDB) Change in Accured Expenses (2017 - 2026)

Solid Biosciences has disclosed Change in Accured Expenses across 10 years of filings, most recently posting -$473000.0 for Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$473000.0, down 72.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.9 million (down 9.96% YoY), and the FY2025 annual result was $4.0 million, down 15.02% from the prior year.
• Change in Accured Expenses came in at -$473000.0 for Q1 2026 at Solid Biosciences, down from $152000.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $8.7 million in Q2 2022 to a low of -$5.0 million in Q3 2022.
• The 5-year median for Change in Accured Expenses is $152000.0 (2025), against an average of $424000.0.
• Peak annual rise in Change in Accured Expenses reached 1515.01% in 2022, while the deepest fall reached 1544.37% in 2022.
• Solid Biosciences' Change in Accured Expenses stood at $2.6 million in 2022, then sank by 164.03% to -$1.6 million in 2023, then soared by 198.72% to $1.6 million in 2024, then sank by 90.64% to $152000.0 in 2025, then sank by 411.18% to -$473000.0 in 2026.
• The last three Change in Accured Expenses figures came in at -$473000.0 (Q1 2026), $152000.0 (Q4 2025), and $2.2 million (Q3 2025), per Business Quant data.